SpringWorks Therapeutics, Inc. (SWTX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Stamford, CT, United States. El CEO actual es Saqib Islam.
SWTX tiene fecha de IPO 2019-09-13, 368 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $3.54B.
SpringWorks Therapeutics, Inc. is a biopharmaceutical company founded in 2017 that acquires, develops, and commercializes medicines targeting underserved patient populations with rare diseases and cancer. The company's lead product candidate, nirogacestat, is an oral gamma secretase inhibitor currently in Phase III clinical trials for desmoid tumors, while its clinical pipeline includes mirdametinib, a MEK inhibitor being evaluated for neurofibromatosis type 1-associated plexiform neurofibromas and solid tumors, as well as BGB-3245 for BRAF-mutant cancers. SpringWorks has established strategic collaborations and licensing agreements with major pharmaceutical companies including BeiGene, GlaxoSmithKline, Pfizer, and others to advance combination therapies and expand its therapeutic capabilities. Headquartered in Stamford, Connecticut, the company focuses on developing innovative small molecule inhibitors across multiple oncology and rare disease indications.
